1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Scancell Holdings plc

Scancell Holdings plc

SCLP.L
Scancell Holdings plcGB flagLondon Stock Exchange
14.75
GBp
+0.50
- -
153.07MMarket Cap
Scancell Holdings plc
SCLP.L
(London Stock Exchange)

Recent

price

14.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
Revenue per Share
-0.02
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
-0.01
-0.01
-0.01
Basic EPS, GAAP
-0.01
-0.01
- -
-0.01
-0.01
-0.01
-0.01
-0.01
-0.01
-0.02
-0.01
-0.01
-0.01
-0.01
-0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-0.02
-0.02
-0.03
-0.03
-0.04
-0.05
-0.06
-0.06
-0.06
-0.07
-0.08
-0.08
-0.09
-0.1
-0.1
Book Value per Share
0.02
0.01
0.02
0.01
0.03
0.01
0.03
0.01
0.03
0.01
0.01
0.01
- -
-0.02
- -
- -
Tangible Book Value per Share
110
164
191
200
223
231
233
268
320
395
466
679
816
816
862
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-226.14
- -
-318.42
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
Depreciation Expense
-2
-2
1
-2
-2
-2
-3
-4
-4
-6
-6
-15
-5
-12
-6
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-226.45
- -
-260.5
Profit Margin (%)
3
1
3
2
6
3
7
3
10
6
4
42
26
17
15
21
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15
17
18
18
- -
LT Debt
6
5
7
5
9
7
10
6
14
9
8
9
1
-10
-4
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
22.6%
24.97%
-49.97%
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
TC Biopharm (Holdings) Plc (TCBP)
Shattuck Labs, Inc. (STTK)
Soligenix Inc. Warrant (SNGXW)
Lyra Therapeutics, Inc. (LYRA)
Kringle Pharma, Inc. (4884.T)
Vertex Pharmaceuticals Incorporated (VX1.DE)
Business
Scancell Holdings plc (LSE:SCLP) is a clinical-stage biopharmaceutical company that develops novel immunotherapies targeting cancer through proprietary platforms including ImmunoBody and Moditope for vaccines; GlyMab and AvidiMab for monoclonal antibodies. ImmunoBody vaccines, such as SCIB1, iSCIB1+, SCIB2, SC129 and SC134, stimulate CD4 and CD8 T-cell responses against tumor-specific peptides to induce potent, durable anti-tumor immunity in solid tumors including metastatic melanoma; Moditope vaccines, such as Modi-1 and Modi-2, target citrullinated and homocitrullinated peptides to harness T-cell responses against a broad range of solid tumors; GlyMab antibodies, including SC2811 and SC27, enhance antibody-dependent cellular cytotoxicity by modifying glycan structures on monoclonal antibodies; AvidiMab enhances antibody potency through molecular modifications. The company, founded in 1996 and headquartered at Bellhouse Building, Oxford Science Park, Oxford, England, operates primarily in the United Kingdom with a pipeline focused on unmet needs in oncology across multiple solid tumor indications. Recent developments include a partnership with the NHS Cancer Vaccine Launchpad for fast-tracked access to SCOPE trials in melanoma patients; a strategic alliance with PharmaJet for the Stratis needle-free injectable device in iSCIB1+ studies; a second commercial license agreement with Genmab yielding $6 million upfront and potential milestones of $630 million plus royalties, validating the GlyMab platform; incorporation of GlyMab Therapeutics Limited as a wholly-owned subsidiary in June 2025; and accelerated plans for randomized registration studies of iSCIB1+ starting in 2026 following Phase 2 data.

Company News

APIChatGPT

  • defenseworld.net

    Scancell (LON:SCLP) Shares Down 3.1% – Here’s What Happened